A first-in-class, first-in-human phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with metastatic refractory solid tumors.

@article{Richards2011AFF,
  title={A first-in-class, first-in-human phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with metastatic refractory solid tumors.},
  author={Jon M. Richards and Michael A Warso and Divyesh G Mehta and Konstantin T Christov and C M Schaeffer and Tohru Yamada and Craig W. Beattie and Linda R. Bressler and Tapas K. Das Gupta},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={2511}
}
2511 Background: A 28 aa peptide (p28) derived from azurin, a redox protein secreted from the opportunistic pathogen Pseudomonas aeruginosa, preferentially enters a wide variety of cancer cells and inhibits their proliferation at G2/M through a non HDM2 mediated post translational increase in the level of wild type and mutated p53. METHODS Refractory (Stage IV) solid tumor patients (15) with p53+ lesions (>10% cells; IHC) were enrolled in an escalating, 5 dose level (.83, 1.66, 2.5, 3.33 and… CONTINUE READING